

SUPPLEMENTAL MATERIAL

Supplementary Table S1. Coronary artery spasm and associated characteristics after provocation test according to vasodilator

	All (n = 1048)	Nitrates (n = 239)	Other types of vasodilator (n = 809)	<i>p</i> value
<i>Location of spasm</i>				
Location of spasm (>2.5 mm vessel) LM	4 (0.4)	0 (0.0)	4 (0.5)	0.579
Location of spasm (>2.5 mm vessel) LAD	511 (48.9)	126 (52.7)	385 (47.8)	0.184
Location of spasm (>2.5 mm vessel) LCx	235 (22.5)	46 (19.2)	189 (23.5)	0.169
Location of spasm (>2.5 mm vessel) RCA	509 (48.8)	127 (53.1)	382 (47.5)	0.123
Associated ECG change	138 (13.2)	36 (15.1)	102 (12.6)	0.324
Associated chest pain	620 (59.2)	164 (68.6)	456 (56.4)	0.001
Associated arrhythmia [†]	149 (14.2)	28 (11.7)	121 (15.0)	0.207
Associated cardiac arrest	3 (0.3)	0 (0.0)	3 (0.4)	1.000

[†] Atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular tachycardia, or atrioventricular block.

ECG, electrocardiography; LAD, left anterior descending coronary artery; LCx, left circumferential artery; LM, left main coronary artery; RCA, right coronary artery.

Supplementary Table S2. Time to composite clinical outcome in nitrate group and other types of vasodilator group

Time to event	Nitrates (n = 10)	Other types of vasodilator (n = 13)
Patient #1	40days	40days
Patient #2	47days	70 days
Patient #3	227days	96 days
Patient #4	230 days	119 days
Patient #5	241 days	171 days
Patient #6	269 days	295 days
Patient #7	330 days	327 days
Patient #8	333 days	331 days
Patient #9	340 days	359 days
Patient #10	357 days	366 days
Patient #11		369 days
Patient #12		380 days
Patient #13		380 days

Supplementary Table S3. One-year clinical event rate of patients with VA according to types of vasodilator in other types of vasodilator

	Nicorandil (n = 521)	Molsidomine (n = 177)	Trimetazidine (n = 111)	<i>p</i> value*
Composite events	12 (3.1)	1 (0.8)	0 (0.0)	0.118
ACS	9 (2.3)	0 (0.0)	0 (0.0)	0.094
Cardiac death	0 (0.0)	1 (0.6)	0 (0.0)	0.484
VT or VF	1 (0.3)	0 (0.0)	0 (0.0)	0.772
AV block	2 (0.5)	0 (0.0)	0 (0.0)	0.595
All-cause death	0 (0.0)	1 (0.8)	1 (1.2)	0.127
Readmission or emergency room visits due to angina	41 (10.5)	21 (17.4)	3 (3.7)	0.009

ACS, acute coronary syndrome; AV, atrioventricular; VA, vasospastic angina; VF, ventricular fibrillation; VT, ventricular tachycardia

* Chi-square test

Supplementary Table S4. Baseline characteristics after propensity matching

	All (n = 348)	Nitrate (n = 174)	Other types of vasodilator (n = 174)	p value
Age, years	52.1 ± 11.3	53.5 ± 11.1	52.8 ± 11.4	0.585
Male, n (%)	237 (68.1)	119 (68.4)	118 (67.8)	1.000
BMI, kg/m ²	24.7 ± 3.6	24.7 ± 3.8	24.8 ± 3.4	0.815
SBP, mmHg	126.5 ± 18.5	127.4 ± 19.6	125.6 ± 17.4	0.372
DBP, mmHg	77.7 ± 12.7	78.2 ± 13.8	77.2 ± 11.5	0.483
Previous CAD, n (%)	23 (6.6)	12 (6.9)	11 (6.3)	0.829
Diabetes mellitus, n (%)	22 (6.3)	14 (8.0)	8 (4.6)	0.186
Hypertension, n (%)	145 (41.7)	78 (44.8)	67 (68.5)	0.232
Dyslipidemia, n (%)	70 (20.1)	35 (20.1)	35 (20.1)	1.000
Alcohol drinking, n (%)	205 (58.9)	103 (59.2)	102 (58.6)	1.000
Current smoking, n (%)	138 (39.7)	67 (38.5)	71 (40.8)	0.661
<i>Previous cardiovascular medication</i>				
Antiplatelet, n (%)	49 (14.1)	26 (14.9)	23 (13.2)	0.644
Statin, n (%)				
CCB, n (%)	65 (18.7)	35 (20.1)	30 (17.2)	0.492
<i>Clinical diagnosis before ergonovine</i>				
Angina, n (%)	324 (93.1)	166 (65.4)	158 (90.8)	0.091
Myocardial infarction, n (%)	10 (2.9)	3 (1.7)	7 (4.0)	0.337
Cardiac arrest, n (%)	2 (0.6)	2 (1.1)	0 (0.0)	0.499
Syncope, n (%)	5 (1.4)	4 (2.3)	1 (0.6)	0.371
VT or VF, n (%)	1 (0.3)	1 (0.6)	0 (0.0)	1.000
AV block, n (%)	1 (0.3)	0 (0.0)	1 (0.6)	1.000

AV, atrioventricular; BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel blocker; DBP, diastolic blood pressure; SBP, systolic blood pressure; VF, ventricular fibrillation; VT, ventricular tachycardia.

Supplementary Table S5. One-year clinical event rate of patients with good drug compliance

	All (n = 491)	Nitrate (n = 104)	Other types of vasodilator (n = 387)	<i>p</i> value
Composite events	10 (2.0)	4 (3.8)	6 (1.6)	0.231
ACS	7 (1.4)	2 (1.9)	5 (1.3)	0.643
Cardiac death	-	-	-	-
VT or VF	1 (0.2)	1 (1.0)	0 (0.0)	0.212
AV block	2 (0.4)	1 (1.0)	1 (0.3)	0.379
All-cause death	2 (0.4)	1 (1.0)	1 (0.3)	0.379

ACS, acute coronary syndrome; AV, atrioventricular; VF, ventricular fibrillation; VT, ventricular tachycardia.

Supplementary Table S6. One-year clinical event rate of patients with poor-compliance during 1 year

	All (n = 285)	Nitrate (n = 82)	Other types of vasodilator (n = 203)	<i>p</i> value
Composite events	13 (4.6)	6 (7.3)	7 (3.4)	0.156
ACS	10 (3.5)	6 (7.3)	4 (2.0)	0.036
Cardiac death	1 (0.4)	0 (0.0)	1 (0.5)	1.000
VT or VF	1 (0.4)	0 (0.0)	1 (0.5)	1.000
AV block	1 (0.4)	0 (0.0)	1 (0.5)	1.000
All-cause death	1 (0.4)	0 (0.0)	1 (0.5)	1.000

ACS, acute coronary syndrome; AV, atrioventricular; VF, ventricular fibrillation; VT, ventricular tachycardia.